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Abstract: Mucocutaneous candidiasis is frequently one of the first signs of human 
  immunodeficiency virus (HIV) infection. Over 90% of patients with AIDS will develop oropha-
ryngeal candidiasis (OPC) at some time during their illness. Although numerous antifungal 
agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole, 
voriconazole, posaconazole) have replaced older topical antifungals (gentian violet and nystatin) 
in the management of oropharyngeal candidiasis in these patients. The systemic azoles, are 
generally safe and effective agents in HIV-infected patients with oropharyngeal candidiasis. 
A constant concern in these patients is relapse, which is dependent on the degree of immunosup-
pression commonly seen after topical therapy, rather than with systemic azole therapy. Candida 
esophagitis (CE) is also an important concern since it occurs in more than 10% of patients with 
AIDS and can lead to a decrease in oral intake and associated weight loss. Fluconazole has 
become the most widely used antifungal in the management of mucosal candidiasis. However, 
itraconazole and posaconazole have similar clinical response rates as fluconazole and are also 
effective alternative agents. In patients with fluconazole-refractory mucosal candidiasis, treat-
ment options now include itraconazole solution, voriconazole, posaconazole, and the newer 
echinocandins (caspofungin, micafungin, and anidulafungin).
Keywords: oropharyngeal candidiasis, esophageal candidiasis, HAART, antifungal agents, 
HIV , AIDS
Introduction
Fungi are found ubiquitously in nature in association with plants and mammals. 
Accordingly, humans are continually exposed to multiple genera of fungi via various 
routes, but particularly by the ingestion of food, allowing for the colonization of the 
gastrointestinal tract. Depending on the interaction between the host’s mucosal defense 
mechanisms, fungal virulence factors, and antifungal utilization, colonization may 
be transient or persistent and local disease may ensue.
Of the numerous pathogenic fungi, Candida is the dominant genus responsible 
for fungal diseases in humans.1 Candida albicans is the species with the highest 
prevalence among human yeast isolates and is the main opportunistic yeast pathogen 
in most warm-blooded animals.1
Symptomatic mucosal candidiasis (MC) arises in subjects colonized with Candida 
who are predisposed by illness, debility, or a local reduction in host resistance to an 
overgrowth of their own indigenous flora. Candida species are frequently isolated from 
the oral cavity and are detected in 31%–60% of healthy individuals.1,2 Colonization 
rates generally increase with the severity of illness and duration of hospitalization.3  HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
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In a recent study, the frequency of oral yeast carriage in the 
competent host varied as a function of age.2 The colonization 
rates increase from 24% in persons aged 5–7 years, to 59% 
in persons above the age of 60. In the hospitalized non-HIV 
infected individual, C. albicans accounted for 70%–80% of 
oral isolates and C. glabrata and C. tropicalis each repre-
sented approximately 5%–8%, while the other non-albicans 
Candida species were recovered only rarely.4,5
In the past decade, there has been a significant increase in 
the frequency of non-albicans Candida species isolated from 
HIV-infected individuals with MC.6,7 In the 1980’s, non-albi-
cans Candida species accounted for 3.4% of oral isolates from 
HIV-infected patients, while in the 1990’s, 16.8% of isolates 
recovered from HIV patients were non-albicans Candida spe-
cies.6,7 The more commonly recovered non-albicans Candida 
species, include C. glabrata, C. parapsilosis, C. tropicalis, 
and C. dubliniensis. In 5%–10% of circumstances multiple 
Candida species may be recovered from a single specimen. 
The more common combinations include C. albicans with C. 
glabrata, C. krusei, C. dubliniensis, or C. tropicalis.
Several local and systemic host and exogenous factors 
increase the prevalence of gastrointestinal (GI) tract Candida 
carriage and population levels.8 The acuteness and extent of 
candidal infections increase with the number and severity of 
predisposing factors. The role of CD4+ T cells is to be the 
normal gastrointestinal mucosal defense mechanism against 
Candida species and this relation is highlighted by the fre-
quent occurrence of oropharyngeal candidiasis (OPC) and 
esophageal candidiasis (EC) in patients with low CD4+ T cells 
and acquired immunodeficiency syndrome (AIDS).8,9 In HIV 
infection, oral carriage of yeast and risk of mucosal invasion 
increase with a progressive reduction in CD4+ T cells.8,10 The 
anti-Candida protective mechanism of CD4+ T cells at a 
mucosal level is still incompletely understood. Recently, 
investigators have shown that cytokines, especially gamma 
interferon, can inhibit the transformation of Candida blas-
toconidia to the more invasive hyphal phase.8,11 In addition, 
several investigators have shown that a decrease in E-cadherin 
levels and a loss of CD4+ T cells in the mucosa are associated 
with episodes of acute OPC.12 The most commonly reported 
cause of higher GI yeast carriage rates and symptomatic oral 
candidiasis is the use of antibiotics.1,8 Elimination of bacterial 
competition is almost certainly the important mechanism by 
which antibiotics affect Candida numbers in vivo.
It is important to note that the introduction of highly 
active antiretroviral therapy (HAART), including protease 
inhibitors, has significantly reduced the prevalence of 
oropharyngeal and esophageal candidiasis in HIV-infected 
patients. In the first 12–24 months after the introduction of 
HAART, the prevalence of OPC decreased from 50%–80% 
down to ∼10%.13 In addition, a decrease of 25%–50% in the 
occurrence of EC was also documented. Unfortunately, there 
have been no further studies describing the epidemiology, 
incidence, or significance of either OPC or EC since 2004.
Based upon epidemiological studies, it is apparent that 
humans are exposed repeatedly to Candida in food and other 
sources. The natural history of this commensal   “normal” 
colonization over weeks, months, and years is poorly under-
stood. Nevertheless, one may reasonably conclude that 
Candida colonization is almost universal.
Oropharyngeal candidiasis
Oral candidiasis has been known since the era of Hippocrates, 
although Hippocrates used the term “aphthae” to describe this 
infection.1 Several clinical forms of oral candidiasis exist; 
thrush is the most commonly and widely recognized and is 
also called acute pseudomembranous candidiasis   (Figure 1). 
Oropharyngeal candidiasis remains the most frequent oppor-
tunistic fungal infection among HIV-positive patients and is 
frequently the initial manifestation of HIV infection. Currently, 
it is estimated that approximately 80%–90% of HIV-infected 
patients develop OPC at some time during the progression of 
their disease from HIV infection to AIDS.1,13,14,15
C. albicans is the species responsible for the majority of 
cases of OPC.1,15 The ability of C. albicans to adhere to buccal 
epithelial cells is critical in establishing oral colonization. After 
colonization, the organisms may persist for months or years in 
low numbers in the absence of inflammation. These low num-
bers are the result of effective host defense mechanisms in the 
oral cavity. Genotyping of Candida strains obtained from HIV-
infected patients with either OPC or EC indicate a genotype 
distribution frequency similar to that seen in non-HIV-infected 
subjects, suggesting that HIV-associated MC is not caused by 
a unique or particularly virulent strain of Candida, but likely 
results from defects in host defense mechanisms.16
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Symptoms of OPC can be extremely variable and range from 
asymptomatic oral lesions, to a sore, painful mouth, a burning 
tongue, and associated dysphagia. Clinical signs include diffuse 
erythema and white patches that appear as discrete lesions on 
the surfaces of the buccal mucosa, throat, tongue, and gums.1,14 
Severe OPC may ultimately impair quality of life and result in a 
reduction of fluid or food intake. The most serious complication 
of untreated OPC is extension of the infection into the esophagus 
resulting in decreased nutritional intake.
Candida esophagitis
Candida is the most common cause of infectious esophagitis 
and, after the oropharynx, the esophagus is the second most 
common site of gastrointestinal candidiasis. The prevalence 
of Candida esophagitis (CE) has increased mainly because of 
its association with HIV-infected individuals. Approximately 
10%–15% of patients with AIDS will eventually suffer from 
this entity during their lifetime.1,15,17–19
The same organisms that are recovered from the esopha-
geal surface are generally the same organisms identified in 
oral secretions. C. albicans remains the most common organ-
ism identified in CE. In contrast to oral candidiasis, little is 
known about host and yeast factors operative in the pathogen-
esis of esophageal candidiasis and experimental models have 
not been established. However, it is likely that the usual yeast 
virulence factors and defects in host defense mechanisms are 
responsible. Esophageal candidiasis in HIV-positive patients 
may be the first manifestation of AIDS. The high prevalence 
of esophagitis in connection to AIDS indicates the critical 
role of cell-mediated immunity in normally protecting the 
esophagus from Candida invasion. Candida esophagitis 
tends to occur later in the natural history of HIV infection 
and almost invariably at lower CD4+ T cell counts (range 
10–105, mean 79, median 30 cells).1,17–19 It is not uncommon 
for patients with advanced AIDS, and near the end of life, 
suffering from severe esophageal candidiasis manifested by 
the inability to have any form of oral intake.
Candida esophagitis commonly causes dysphagia, 
odynophagia, and retrosternal pain. Although CE may arise 
as an extension of OPC, in approximately 10% of cases the 
esophagus maybe the only site involved affecting the distal 
two-thirds, rather than the proximal one-third, which is the 
area more commonly affected (Figure 2). An occasional fea-
ture of CE is the complete lack of clinical symptoms despite 
extensive objective esophageal involvement.1,17–19
A reliable diagnosis can only be made by direct 
visualization of the esophagus along with histological evi-
dence of tissue invasion in biopsy material.22,21 However, 
clinical criteria may be accepted as a basis for initiating 
antifungal therapy in high risk patients. The differential 
diagnosis of EC must include gastroesophageal reflux disease 
(GERD), idiopathic HIV-ulcers, and viral esophagitis due to 
either cytomegalovirus or herpes simplex virus.1,20,21
Therapy
Numerous antifungal agents are available for the treatment 
of OPC and EC in the HIV-positive patient (Tables 1 and 2). 
In addition, guidelines for the management of mucosal candidi-
asis in HIV-infected patients have been published by the Centers 
for Disease Control, National Institutes of Health, and the HIV 
Medicine Association of the Infectious Diseases Society of 
America.22 However, several factors should be   considered when 
selecting antifungal agents for patients with HIV   infection. 
In HIV-positive patients, antifungals are frequently less effica-
cious than in patients with other immunodeficiencies such as 
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Table 2 Antifungals for esophageal candidiasis
Antifungal agent Form Strength Usage
Azoles
Ketoconazole Tablets 200 mg 1–2 tablets, once to 
twice daily
Fluconazole Tablet  
SolutionIV piggyback
100 mg 
10 mg/mL
1 tablet daily 
10 mL, once daily 
100 mg, once daily
Itraconazole Capsule 
Solution
100 mg 
10 mg/mL
2 capsules, once daily 
20 mL, once daily
Posaconazole Suspension 100 mg/2.5 mL 4 tsp, twice daily
Voriconazole Tablet/IV piggyback 200 mg Once daily
Caspofungin Intravenous 50 mg Once daily
Micafungin Intravenous 150 mg Once daily
Anidulafungin Intravenous 50 mg Once daily
Amphotericin B Intravenous 0.3–0.7 mg/kg Once daily
Table 1 Antifungals for oropharyngeal candidiasis*
Antifungal agent Form Strength Usage Cost
Topical
Nystatin Pastille 
Suspension
200 000 units 1–2 pastilles, 4 times daily 
5 mL swish-and-Swallow, 
4 times daily
+ 
+ 
+
Clotrimazole Oral troche 10 mg troche Dissolve 1 troche, 5 
times daily
+
Amphotericin B Suspension 
Lozenge 
Tablet
1 mg/mL 
100 mg 
10 mg
1 mL swish-and- 
swallow, 4 times daily 
Four times daily 
Four times daily
+ 
+ 
+
Miconazole 
(Lauriad®)
Lauriad 10 mg Apply to gum once daily TBD
Systemic 
Ketoconazole Tablet 200 mg 1–2 tablets, once to 
twice daily
+
Fluconazole Tablet 
Solution
100 mg 
10 mg/mL
1 tablet daily 
10 mL, once daily
++ 
++
Itraconazole Capsule 
Solution
100 mg 
10 mg/mL
2 capsules, once daily 
10–20 mL, once daily
++ 
++
Posaconazole Suspension 100 mg/2.5 mL 2 tsp daily +++
Notes: *Oral therapy preferred when tolerated. Cost index: (+) inexpensive; (++) modest expense; (+++) expensive; TBD = to be determined.
cancer. Similarly, the time to clinical response also tends to be 
delayed in this population.17,22,23 Moreover, the relapse rate is 
higher in patients with HIV than in any other patient popula-
tion.1,17,22,23 For unknown reasons, a subgroup of HIV-positive 
patients experience recurrent episodes of OPC and thus receive 
numerous courses of antifungals during their lifetime. As 
their HIV infection progresses they tend to experience shorter 
disease-free intervals between episodes of mucosal candidiasis 
and thus have greater antifungal exposure, which may ultimately 
lead to the development of clinical and in vitro antifungal resis-
tance and its associated morbidity and mortality.
It is important to note that, as with some opportunistic 
pathogens in this patient population, antifungal treatment 
merely reduces the signs and symptoms of infection and thus 
produces a transient clinical response by lowering the quantity 
of organisms in the affected area. It is extremely   difficult to 
fully eradicate Candida from the mucosal surfaces of patients 
who are immunocompromised, especially those who are HIV-
positive.8,18,23 The combination of frequent clinical relapses and 
increased antifungal utilization are frequently associated with 
antifungal resistance.24 This is reflected, clinically, by the inef-
fectiveness of antifungals to which a patient has not previously 
been exposed. Thus, we are becoming increasingly aware that 
choosing the appropriate agent, even in the early stages of dis-
ease, is extremely important because of the future repercussions 
of these selections in advanced stages of infection.HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
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Classes of agents used in the treatment of MC in HIV 
includes the polyenes (eg, amphotericin B, nystatin), pyrimi-
dine synthesis inhibitors (flucytosine), azoles (miconazole, 
clotrimazole, ketoconazole, itraconazole, fluconazole, voricon-
azole, posaconazole), and, more recently, the echinocandins 
(caspofungin, micafungin, anidulafungin).17,22,24 Common 
  dosage regimens of these agents are listed in Tables 1 and 2.
The key trials evaluating antifungals in the treatment of OPC 
and EC are summarized in Table 3. Most controlled studies to 
date have evaluated the azole antifungal agents and in general, 
clinical response rates appear to be similar. Clinical response 
varies widely, as does the rate of relapse. Studies of antifungal 
treatment in MC can be problematic to evaluate, particularly in 
the HIV-positive population. Limitations often include a small 
number of patients, open label design, and a short follow-up 
time. Additional studies are particularly needed among patients 
with low CD4+ T lymphocyte counts, as this population tends 
to have lower clinical and mycological response rates. A recent 
meta-analysis suggested that larger studies using more consis-
tent outcome measures and reporting would be helpful in apply-
ing future research to current clinical practice.25 Additionally, 
these authors also suggested that future investigations should 
include less expensive antifungal interventions and, at the same 
time, evaluate symptom-free periods, quality of life, survival, 
and the development of clinical and in vitro resistance.
Therapy of oropharyngeal candidiasis
Prior to the development of the polyenes and the azoles, topi-
cal therapy consisted of gentian violet applications that were 
reasonably effective in localized MC, but were extremely 
messy because of the purple color.24,26
While topical therapies have historically been effective in 
less severe disease and are relatively inexpensive compared 
to some of the systemic therapies, their use has diminished 
Table 3 Clinical trials of antifungal agents for the treatment of OPC and eC in HIV-positive patients
Authors Regimens evaluated 
(n = number of subjects)
Clinical response Relapse rate
Oropharyngeal candidiasis (OPC)
Dewit et al37  Fluconazole 50 mg/day (n = 17) 
Ketoconazole 200 mg/day (n = 16)
100% 
75%
46% at 30 days 
11%
Smith et al106  Ketoconazole 200 mg BID (n = 40) 
Itraconazole 200 mg/day (n = 46)
93% 
93%
.80% at 90 days 
.80%
Barchiesi et al107  Fluconazole 200 mg/day (n =38) 
Ketoconazole 400 mg/day (n = 39)
42% 
34%
62% 
22%
Pons et al30  Fluconazole 100 mg/day (n = 152) 
Clotrimazole 10 mg 5/day (n = 136)
98% 
48%
34% at 42 days 
40%
de Repentigny et al108 Ketoconazole 200 mg/day (n = 52) 
Itraconazole 200 mg/day (n = 46)
60% 
71%
80% at 60 days 
80% at 60 days
Vazquez et al58  Fluconazole 100 mg/day (n = 94) 
Posaconazole 50 mg/day (n = 98) 
Posaconazole 100 mg/day (n = 102) 
Posaconazole 200 mg/day (n = 91) 
Posaconazole 400 mg/day (n = 100)
51% 
74% 
80% 
74% 
83%
37% at 30 days 
41% 
38% 
35% 
36%
Vazquez et al32  Miconazole lauriad 10 mg/day (n = 283) 
Clotrimazole 10 mg 5/day (n = 281)
68% 
74%
27% 
28%
Esophageal candidiasis (EC)
Laine et al66  Ketoconazole 200 mg/day (n = 71) 
Fluconazole 100 mg/day (n = 72)
65% 
85%
N/A
de Repentigny et al108 Ketoconazole 200 mg/day (n = 19) 
Itraconazole 200 mg/day (n = 12)
100% 
65%
58% at 60 days 
82% at 60 days
Ally et al72 Fluconazole 200 mg/day (n = 141) 
Voriconazole 200 mg BID (n = 115)
90% 
95%
N/A
Villaneueva et al77  Fluconazole 200 mg/day (n = 94) 
Caspofungin 50 mg/day (n = 81)
89% 
90%
17% at 28 days 
28% at 28 days
de wet et al78  Fluconazole 200 mg/day (n = 60) 
Micafungin 50 mg/day (n = 64) 
Micafungin 100 mg/day (n = 62) 
Micafungin 150 mg/day (n = 59)
80% 
84% 
92% 
92%
N/A
Krause et al79 Fluconazole 400 mg/day (n = 255) 
Anidulafungin 200 mg then 100 mg/day (n = 249)
99% 
99%
11% at 14 days 
36% HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
94
Vazquez
due to poor tolerability and poor adherence. Topical therapy 
of OPC can be accomplished with a multitude of antifungal 
agents including nystatin, amphotericin B, clotrimazole, and, 
more recently, miconazole (Table 1).17,22,24,26–31 Nystatin is 
available in several formulations, including pastilles and sus-
pension. Limitations of topical agents such as nystatin include 
a bitter taste, GI-adverse effects, and frequent dosing, all of 
which may contribute to reduced adherence.24,27 Importantly, 
nystatin has not demonstrated significant efficacy in severely 
immunocompromised patients, such as those with advanced 
HIV infection.27,28 For instance, in HIV-positive patients, nys-
tatin exhibited lower rates of both clinical cure (52% vs 87%) 
and mycological cure (6% vs 60%) when compared to oral 
fluconazole. Additionally, the 28- day relapse rate was found 
to be greater with nystatin (44% vs 18%) when compared 
to fluconazole.27
Amphotericin B is also an option for topical therapy 
and is available in suspension, lozenge, and tablet form.1,22 
Neither nystatin, nor amphotericin B is absorbed from the 
gastrointestinal tract so administration must be frequent (four 
times daily) to provide adequate drug exposure to the infected 
mucosal tissues.1,22 Prospective, comparative studies evaluat-
ing amphotericin B oral solution against other antifungals are 
limited. Topical azole antifungal agents, such as clotrimazole 
10 mg troches, administered five times daily, provide another 
option for OPC patients. Topical clotrimazole has been used 
successfully in treating mild-to-moderate OPC during the 
early stages of HIV disease.28–30
The newest topical antifungal is the mucoadhesive buccal 
tablet (MMBT) containing 50 mg of miconazole (Loramyc®).31 
This novel formulation of miconazole has been approved in 
Europe since 2008 for the treatment of OPC in immucocom-
promised hosts. The formulation is unique, because 50 mg of 
miconazole is contained in each mucoadhesive tablet and is 
applied to the mucosa of the upper gum over the canine fossa, 
once daily, for 7–14 days. The MMBT adheres to the gum 
surface because of the milk protein concentrate composition of 
the tablet. This interaction leads to a rapid and prolonged adhe-
sion to the mucosa due to an adsorption mechanism, followed 
by a protein-protein interaction. In pharmacokinetic studies, 
50 mg of MMBT provides a maximum salivary concentra-
tion of 15 µg/mL, up to seven hours after the application of 
the tablet.31 Three separate clinical studies have evaluated the 
use of MMBTs for the treatment of OPC in the HIV-positive 
population and in patients with head and neck cancers.32–34 
In a phase III, double-blind, double-dummy, multicenter trial 
evaluating 578 patients with HIV and OPC, MMBT treatment 
was compared to clotrimazole troches (10 mg, five times daily, 
for a period of 14 days).32 The results at the primary endpoint of 
test of cure (TOC) in both the intent-to-treat (ITT) population 
and in the per-protocol population (PP) demonstrated that the 
once daily administration of a MMBT was as effective as the 
five times daily clotrimazole treatment. Clinical cure rates at 
TOC in both the ITT (61% vs 65%) and PP (68% vs 74%) 
populations demonstrated no inferiority to clotrimazole. In 
addition, secondary endpoints such as safety and tolerability 
were similar between both treatment groups.
The use of topical antimycotic agents has been replaced with 
systemic azole antifungals such as ketoconazole, fluconazole, 
itraconazole, and more recently posaconazole (Table 1).17,24 Part 
of the reason for this is that, although clinical cure rates may 
be similar, microbiologic cure and long term efficacy are not. 
In one example, a study comparing systemic oral fluconazole 
with clotrimazole troches in HIV-positive adults found clinical 
efficacy to be similar (98% vs 94%). However, microbiologi-
cal cure rates were greater in patients treated with fluconazole 
(65% vs 48%) and clinical response sustained through a 2-week 
follow up was also greater (82% vs 50%).30
The currently available systemic azoles include keto-
conazole, fluconazole, itraconazole, and posaconazole. 
Ketoconazole was the first available oral systemic imidazole 
antifungal agent with high rates of efficacy in OPC.35,36 
  However, in comparative trials, ketoconazole was found 
to be less efficacious then fluconazole in both clinical and 
mycological cure rates.37 In addition, the use of ketoconazole 
is further limited by potentially severe adverse reactions 
including hepatotoxicity, poor oral bioavailability, and a 
host of drug–drug interactions.36 Ketoconazole is a very 
potent inhibitor of cytochrome P450 3A4 and is   relatively 
contraindicated with some HIV-protease inhibitors.38 
Because the drug’s absorption is dependent upon an acidic 
pH, there are also concerns that systemic absorption may be 
inadequate in patients receiving acid-suppressive therapy or 
with AIDS-related hypochlorhydria.39 In view of the lower 
clinical efficacy rates and the associated adverse event profile 
(ie, hepatotoxicity), ketoconazole is not widely used anymore. 
In contrast to ketoconazole, other azoles such as fluconazole, 
itraconazole, voriconazole, and posaconazole have demon-
strated improved efficacy, as well as excellent safety profiles, 
and have thus become the drugs of choice for OPC, especially 
in HIV-positive patients (Table 3).1,22,24,30
Fluconazole is the most commonly used antifungal in the 
treatment of MC in HIV-infected patients. It is available in 
oral suspension, tablet, and parenteral formulations. Flucon-
azole is more readily absorbed than other oral azoles without 
being affected by either food or gastric acidity. The clinical HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
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efficacy of fluconazole has been established in many well 
controlled clinical trials, such that it has become the stan-
dard comparator in clinical trials of novel agents.24,30,37,40–42 
Most studies of fluconazole have used an initial loading 
dose of 200 mg followed by 100 mg daily, but clinical suc-
cess has been achieved with doses as low as 50 mg/day.40 
Clinical response is usually apparent within 10 days with 
50 mg/day, and 5 to 7 days for doses of 100–200 mg/day.17,40 
Of the available azoles, fluconazole is associated with the 
fewest drug–drug interactions because it has less affinity for 
the CYP3A4 enzyme.38,43 The pharmacological interactions 
with fluconazole include concomitantly administered pheny-
toin, rifampin, rifabutin, cyclosporin A, and possibly some of 
the protease inhibitors.38,39,43–45 Fluconazole is generally well 
tolerated, however, as with any other azole being used long 
term, periodic surveillance of liver enzymes to monitor for 
hepatotoxicity is useful.24,43
Itraconazole is supplied in a cyclodextrin oral solution or 
capsule; the parenteral formulation is no longer manufactured 
in the United States.1,24,46 Like ketoconazole, itraconazole 
exhibits a strong potential for drug–drug interactions through 
the CPY3A4 enzyme system.38,46,47 The itraconazole oral 
solution has greater bioavailability than the capsule and 
absorption is further enhanced by postprandial administra-
tion.40,46–48 One prospective, randomized trial in HIV-positive 
and AIDS patients with OPC, found itraconazole oral solution 
to have similar efficacy and safety as fluconazole (clinical 
response 97% vs 87%).49 However, approximately 50% of the 
patients in both groups experienced relapses at the 1-month 
follow-up evaluation.
Posaconazole is the newest triazole on the market and 
is approved for the treatment of acute OPC and antifungal-
refractory MC.50–52 It is an oral extended-spectrum triazole 
with potent in vitro activity against pathogenic yeast and 
moulds, including fluconazole- and itraconazole-resistant 
Candida strains.50 As with other azoles, posaconazole inhibits 
lanosterol 14-α-demehylase. It appears that mutations near 
the heme cofactor of CYP51 reduce the binding affinity of 
compact azoles, such as fluconazole and itraconazole, and 
may lead to azole crossresistance.50 However, 3-dimen-
sional binding models suggest that the long side chain of 
posaconazole may result in tighter binding affinity.53,54 Thus, 
posaconazole may be less susceptible than some azoles to the 
development of secondary azole resistance. Posaconazole is 
absorbed in an oral suspension.50 It is important to note that 
posaconazole absorption is enhanced by coadministration 
with food, especially high fatty meals, or with a nutritional 
supplement such as Boost® Plus (Nestlé, Fremont, MI).55,56 
When food intake is limited, dividing the daily dose from 
BID (twice daily) to QID (four times daily) also increases 
the plasma concentration. Unlike itraconazole and voricon-
azole, posaconazole is not primarily metabolized by fungal 
cytochrome P450 enzymes.57 During several drug interaction 
trials evaluating the effects of posaconazole on the CYP450 
enzymes, posaconazole did demonstrate an inhibitory effect 
on CYP3A4, but did not influence the other isoenzymes. 
In a large multicenter, randomized clinical trial, a 100 mg 
daily dose of posaconazole was compared to a 100 mg daily 
dose of fluconazole in HIV-positive patients with OPC.58 
Clinical success was reported in 92% of the posaconazole 
recipients compared with a success rate of 92% for those 
patients that received fluconazole. The only difference was 
in the long-term follow-up, where clinical relapses occurred 
more frequently in the fluconazole group compared to the 
posaconazole group (38.2% vs 31.5%). In general, the 
adverse events reported in both groups were comparable.
Several concerns have been raised about the widespread 
use of the more potent oral azoles, which may offer only 
minor advantages for patients. These concerns include drug 
interactions, side effects, increased expense, and risk of 
developing antifungal resistance. An increased frequency of 
C. glabrata isolation has been described by several investi-
gators of HIV-positive patients receiving prolonged courses 
of fluconazole.59–62 In addition, although azole resistance 
in C. albicans is rare, several reports describe both clinical 
failure and in vitro resistance in both non-HIV patients and 
in HIV-infected patients on long-term azoles.24,63
Therapy of esophageal candidiasis
Systemic antifungal therapy using oral or parenteral flucon-
azole has been the mainstay in the management of EC for over 
a two decades (Tables 2 and 3).1,17 Topical antifungals such as 
nystatin, clotrimazole, and miconazole are of minimal value 
in EC.22,64 The initial step in the management of EC should 
always be to attempt to minimize all possible predisposing 
factors, such as corticosteroids, chemotherapeutic agents, 
and antimicrobials.1,17,22
Oral fluconazole has an excellent safety profile when 
compared to ketoconazole, demonstrates excellent gastric 
absorption, and can also be given intravenously when nec-
essary. Similar to the observations in OPC research, studies 
comparing fluconazole with either clotrimazole or ketocon-
azole for CE demonstrate cure rates that are superior to those 
with other imidazoles. Moreover, fluconazole demonstrated 
a more rapid onset of action and quicker resolution of symp-
toms.65–67 Itraconazole has also been shown to be effective in  HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
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the treatment of EC.68–70 Patients treated with itraconazole 
oral solution (100–200 mg/day) had clinical response rates 
comparable to those of patients treated with fluconazole 
tablets (100–200 mg/day) of 94% and 91%, respectively, 
without significant adverse effects in either group.68 The 
mycological cure rates were also similar at 92% and 78%, 
respectively.
Voriconazole, another broad spectrum systemic triaz-
ole is also approved for the treatment of EC at a dose of 
200 mg BID for 14–21 days. In vitro, it has been shown to 
be 10- to 500-fold more potent than fluconazole against a 
wide array of yeast and moulds, including many isolates that 
have demonstrated in vitro itraconazole- and/or fluconazole-
  resistance.71 In a double-blind, randomized, multicenter study, 
voriconazole 200 mg BID was compared to fluconazole 
200 mg daily in EC.72 The overall success rates were com-
parable at 98.2% for voriconazole vs 95% for fluconazole. 
  Furthermore, the overall safety and adverse event profile of 
both agents was comparable. As with most azoles, voriconazole 
has an effect on the CYP450 enzymes, so caution regarding 
drug-drug interactions is warranted.36,71 A common side effect 
with voriconazole includes photopsia (visual abnormalities) 
that may occur in 20%–30% of patients. These abnormalities 
eventually resolve after 3–4 days of continued usage. Other 
side effects may include elevations in transaminases (∼10%) 
and skin rashes (∼10%), with rare cases of photodermatitis 
in patients who are exposed to direct sunlight.71
Prior to the availability of azole antifungal agents, ampho-
tericin B deoxycholate was used extensively. However, it is 
now rarely used in any patient and is generally reserved for 
antifungal-refractory cases of Candida esophagitis that do not 
respond to azoles or echinocandins.73 If necessary, low dose 
amphotericin B (0.15–0.3 mg/kg/day or 10–20 mg/day for 
10–14 days) is sufficient for moderate to severe disease.1,17,73 
However, because of the improved adverse event profiles 
of the lipid formulations of amphotericin B, they have also 
become popular. Oral flucytosine (100–150 mg/kg/day in 
divided doses), although effective, is rarely used because of 
the tendency for resistance to develop during therapy and the 
well described frequency of bone marrow suppression and 
transaminase elevation.1,74 Furthermore, in one comparative 
clinical trial, clinical efficacy and mycological cure rates were 
lower for flucytosine when compared to fluconazole.74
The echinocandin class of antifungals, which includes 
caspofungin, micafungin, and anidulafungin are a novel 
class of antifungal agents with a completely different 
mechanism of action.75 All three agents have demonstrated 
excellent in vitro activity against a broad array of Candida 
species, including those that are resistant to fluconazole, 
itraconazole, or voriconazole.75 There have been a total of 
five clinical trials evaluating the efficacy of the three echi-
nocandins in treating EC in HIV-positive patients. In all 
studies, the echinocandins are compared to either fluconazole 
or amphotericin B. In a clinical trial comparing caspofungin 
to amphotericin B in both OPC and EC in a population that 
was predominantly HIV-positive, clinical success rates for 
caspofungin ranged from 74% to 91%, which was numeri-
cally greater than the success rate for amphotericin B (63%).76 
In a related study, 177 patients with EC were stratified to 
receive either fluconazole 200 mg/day or caspofungin 50 mg/
day. Caspofungin was found to have similar response and 
relapse rates as fluconazole.77 In another clinical trial, the 
treatment of EC among HIV-positive patients was also found 
to be similar for micafungin 150 mg/day when compared to 
fluconazole 200 mg/day.78 In a separate multicenter clinical 
study in HIV-positive patients (n = 601, 75% with AIDS) 
evaluating anidulafungin versus fluconazole in patients with 
EC found this echinocandin to have similar clinical response 
rates when compared to fluconazole, in terms of both efficacy 
and safety.79 So, while the echinocandins are not considered 
first line therapy for EC, they are effective antifungals for the 
treatment of MC in HIV-positive patients. Their use however, 
is limited because of the lack of an oral formulation.
Clinical relapse is not uncommon, especially in patients 
with persistent underlying immunodeficiency (eg, untreated 
and advanced HIV infection). Relapse appears to depend on 
the duration of antifungal therapy and degree of immunosup-
pression and may occur sooner following clotrimazole and 
ketoconazole therapy than after itraconazole, fluconazole, 
or posaconazole therapy.30,71,80,81 After several recurrences 
of symptomatic OPC in patients with AIDS, clinicians may 
consider maintenance (secondary) prophylaxis.80
Several dosages of fluconazole as the primary prophylaxis 
have been evaluated. Although most studies documented a 
reduction in the frequency of MC in treated patients with 
AIDS, the regimens did not provide complete protection and 
occasional breakthrough infections occurred.82,84 Powderly 
et al compared fluconazole 200 mg/day and clotrimazole 
troches 10 mg five-times/day prophylactically in HIV-positive 
patients.83 Overall, fluconazole reduced the frequency of 
MC, superficial fungal infections, and cryptococcal disease 
when compared to clotrimazole.83 The benefit was greatest in 
patients with less than 50 CD4+ T cells/mm3. Unfortunately, 
in this study, the incidence of in vitro resistance and the 
effect fluconazole had on fungal flora was not evaluated. In 
addition, although the incidence of fungal infections was HIV/AIDS – Research and Palliative Care 2010: 2 submit your manuscript | www.dovepress.com
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reduced, the survival rate was similar in both groups. In this 
setting, one must weigh the benefits against the cost of daily 
drug administration, not only in the financial sense, but also 
the influence of the agent on the patient’s mycoflora.
Schuman et al evaluated fluconazole 200 mg/week 
vs   placebo in HIV-infected women with CD4+ T cell 
counts , 300 cells/mm.85 The study concluded that weekly 
fluconazole was effective in preventing symptomatic OPC and 
vaginal candidiasis while the rates of clinical and in vitro resis-
tance were low. Additionally, women receiving fluconazole 
had a reduction in the colonization rates of C. albicans, but had 
an increased isolation of non-albicans Candida species. In a 
recent multicenter, randomized clinical trial evaluating the role 
of prophylaxis in HIV-positive patients, Goldman et al showed 
that the number of episodes of OPC and other invasive fungal 
infections was statistically lower in HIV-positive patients with 
CD4+ T counts , 150 cells/mm3, when receiving continuous 
(three times a week fluconazole) when compared to those 
patients only receiving episodic treatment with fluconazole 
for OPC recurrences.84 The study also demonstrated that the 
incidence of clinically significant resistance was no higher in 
the group receiving continuous therapy than in the group using 
episodic administration of fluconazole, provided the patients 
were on highly active antiretroviral therapy.
In general, when making the clinical decision to initiate 
secondary prophylaxis the physician should consider several 
key points: the impact of excessive recurrences on the patients 
well being and quality of life, the need for prophylaxis of 
other fungal infections, financial costs, adverse event profiles, 
and drug-drug interactions.
Management of antifungal-refractory 
mucosal candidiasis
The clinical impact of antifungal resistance in patients with 
AIDS has been demonstrated in patients who failed conven-
tional antifungal therapy for MC.24,86 After the development of 
fluconazole-resistant OPC, patients were noted to have a median 
survival of approximately 184 days. Moreover, after the onset of 
clinical resistance to parenteral amphotericin B, patients were 
found to have an astonishing 83-day median   survival rate.24,86 
Although MC per se is not fatal, clinical failure is probably 
a comorbid factor associated with the rapid demise of these 
patients. Clinical failure may also be a marker of severe immu-
nosuppression and a dysfunctional immune system.
Antifungal resistance can be divided into two categories, 
clinical and in vitro. Clinical resistance signifies failure of 
the antifungal to eradicate the infection in the absence of 
in vitro resistance. Such resistance may occur for a variety 
of reasons. In vitro resistance can also be subdivided into 
either primary (innate or intrinsic ) or secondary (acquired) 
resistance.24,86
The usefulness of bacterial in vitro susceptibility   testing is 
well established in the management of patients with infectious 
diseases. However, despite the fact that a subcommittee for 
in vitro antifungal susceptibility testing published approved 
guidelines, the utility of these results in managing fungal 
infections is still somewhat controversial.87,88 Several studies 
have revealed a correlation between the in vitro susceptibil-
ity minimum inhibitory concentration [MIC] results of C. 
albicans and the clinical response to antifungal treatment 
in HIV-infected patients.60,87,88 Investigators have published 
therapeutic antifungal successes and failures in patients with 
OPC and Candida isolates for which MICs were both low and 
high. In fact, one group has reported several HIV-infected 
patients with documented in vitro fluconazole-resistant MC 
who were still able to respond to fluconazole therapy.
Initially, it was believed that the trigger for the emergence 
of resistance was primarily due to the use of low dose flu-
conazole for acute treatment as well as for prophylaxis.86,89,90 
More recently, investigators have demonstrated that MC 
due to resistant isolates is seen in patients with low CD4+ 
cell counts (,50 cells/mm3).91 Conversely, another study 
indicated that a low CD4+ cell count did not predict azole-
resistant MC in patients with AIDS.61
Investigators have be able to identify several key risk fac-
tors associated with the development of fluconazole-resistant 
MC in patients with AIDS, compared to those patients with-
out evidence of fluconazole-resistant MC. These risk factors 
include: greater number of episodes of OPC (6.1 vs 1.8), 
lower median CD4+ cell count (11 vs 71 cells/mm3), longer 
median duration of antifungal therapy (419 vs 118 days), 
and longer duration of systemic azoles (272 vs 14 days).91 
When the authors used two controls matched by CD4+ cell 
count, resistant cases continued to have a greater median 
exposure time to azoles (272 vs 88 days; P = 0.005) as the 
significant risk factor.61,91
It is still not clear whether the total dose of antifungals, 
the duration of therapy, the type of antifungal, and/or the 
pattern of drug administration (continuous vs episodic) 
are the most important determinants in the development 
of antifungal-refractory fungal disease.24,84,90,91 More than 
likely, the etiology is multifactorial involving a combination 
of advanced immunosuppression, high fungal burdens, and 
prolonged exposure time to antifungals.
The management of fluconazole-resistant MC is fre-
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with periodic and rapid recurrences. In some patients, the 
refractory candidiasis may respond to increases in the dose of 
fluconazole (Table 4). For example, if patients fail fluconazole 
200 mg/day, a dosage increase to 400–800 mg/day will fre-
quently produce a clinical response for a period of time. How-
ever, the response is generally transient and the disease recurs 
rapidly once patients have reached this stage. As noted, clinical 
and in vitro azole resistance is not uncommon in patients who 
fail to respond to fluconazole.   Occasionally, in some patients 
with fluconazole-refractory MC, fluconazole suspension may 
be beneficial.91 Several reports describe improvement in these 
patients, possibly associated with increased salivary levels of 
fluconazole, which results when the suspension is taken with 
a swish-and-swallow technique.91
Several clinical trials evaluating itraconazole oral solution 
have demonstrated promising results in patients with AIDS who 
failed fluconazole 200 mg/day.92–95 A clinical cure or improve-
ment occurred in 55%–70% of these patients. As expected, 
mycological cure rates were low (,30%) and relapses following 
treatment cessation were rapid, usually within 14 days.
The two newly expanded spectrum triazoles, voriconazole 
and posaconazole, have been used successfully in patients with 
refractory MC.96,97 Posaconazole is licensed in the United States 
for the treatment of refractory OPC/EC. In the largest clini-
cal trial evaluating antifungal agents for refractory OPC/EC, 
posaconazole 400 mg suspension was given either QD (once 
daily) or BID and was evaluated in subjects with documented 
clinical resistance to either fluconazole or itraconazole.96 Of the 
176 subjects enrolled, 132 (75%) achieved a clinical response 
after 28 days of therapy with very few adverse events. Only 
eight patients discontinued the study drug because of a side 
effect. As expected, during the 4-week follow up period the 
overall clinical relapse rate was 74%.
It is important to note that with any fungal infection in 
patients with advanced HIV infection it is essential to con-
tinue suppressive antifungal therapy in an attempt to increase 
disease-free intervals and avoid morbidity and occasional 
mortality. These patients generally suffer from advanced-HIV 
disease and ultimately very low CD4+ T cells (,50) and high 
viral burdens along with uncontrolled HIV infection.81
It is important not to underestimate the significance of 
the underlying dysfunctional immune system in patients with 
AIDS and refractory fungal infections. Although randomized 
clinical trials have not been done, the initiation of HAART 
will frequently assist in the resolution of these recalcitrant 
infections. In fact, treatment with HAART alone without 
antifungals have eradicated antifungal-refractory OPC in 
patients with advanced HIV infection.98,99
The classic management of infections in the compromised 
host has depended upon antimicrobial agents, without taking 
into account host defects. Several cytokines developed and 
produced by recombinant technology show promise in assist-
ing the host response to fungal infection.100,101 There have 
been several reports describing the use of human recombinant 
granulocyte-macrophage colony stimulating factor (rhuGM-
CSF) in patients with OPC or EC refractory to fluconazole 
and amphotericin B.100,101 Although no large studies have 
been published, case reports describe good response rates 
with rhuGM-CSF in patients with advanced HIV infection 
and refractory mucosal candidiasis.101,102 Further studies 
evaluating these cytokines are certainly warranted.
Alternative therapeutic modalities using organic 
substances are also being administered empirically to com-
bat refractory MC. One of these formulations is Melaleuca 
alternafolia, or Australian tea tree oil that has been formu-
lated into an oral solution. A small, single center pilot study 
evaluating the melaleuca oral solution in 14 patients with 
AIDS and fluconazole-refractory OPC has been completed.103 
The results appear to indicate relatively good efficacy in 
these difficult-to-treat patients, demonstrating a good clinical 
response in 10 of 12 patients after four weeks of antifungal 
therapy. However, larger comparative studies are necessary 
to evaluate the role of this agent in refractory candidiasis.
Table 4 Alternative therapies for the management of antifungal-
refractory mucosal candidiasis in patients with AIDS
Antifungals
• Posaconazole suspension 400 mg twice daily
  o FDA approved for antifungal-refractory mucosal candidiasis
• High dose fluconazole (800–1600 mg/day)
• Itraconazole oral solution 200–300 mg twice daily
• Voriconazole tablets/solution 200–300 mg twice daily
• Amphotericin B deoxycholate 0.3–0.7 mg/kg/day
• Lipid formulations of amphotericin B 1–3 mg/kg/day
• Anidulafungin 100 mg IV daily
• Caspofungin 50 mg IV daily
• Micafungin 150 mg IV daily
Antifungal combinations
• Fluconazole + flucytosine 100 mg/kg day, divided QID
• rhuGM-CSF + fluconazole
• Amphotericin B + echinocandins
• Fluconazole + terbinafine
• Fluconazole + echinocandins
Investigational antifungal agents
• Melaleuca oral solution (Breathaway®)
Note: Many of the alternative therapies are not FDA approved and not supported 
by adequate clinical trials.
Abbreviations: FDA, US Food and Drug Administration; rhuGM-CSF, recombinant 
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In conclusion, significant advances in antifungal therapy 
have been made in the last decade. The impressive clinical 
trial results and the low grade side effect profile of the azole 
compounds continue to make them attractive choices in the 
management of fungal infections in any immunocompro-
mised patient, especially HIV-positive patients. However, 
difficulties in managing these infections should remind us 
that we can not rely solely on antifungals. We must continue 
to find ways to improve the body’s dysfunctional immune 
system. In addition, we must continue to develop more effec-
tive antifungal agents with different mechanisms of action 
and different modes of administration.
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